Vol 7 Issue 6

Gene delivery platform evolution

Jul 2021

Editorial

Expanding gene therapy and gene editing strategies to large and complex indications

Carmen Unzu,

Florie Borel

30 June 2021

Editorial

Innovator Insight

Scalable upstream process development for the suspension-based production of lentiviral vectors for CAR T cell therapies with multiparallel & benchtop bioreactor systems & DoE methodology

Diana Riethmüller,

Dr Alengo Nyamay’antu,

Franziska Bollmann

8 July 2021

Innovator Insight

Interview

Next steps in AAV preclinical and translational R&D

Anna Tretiakova PhD,

Shari Gordon

1 July 2021

Interview

Coming of age: taking the next steps with non-viral gene delivery

Matt Stanton

29 June 2021

Interview

Progressing genetic medicines at the interface of gene therapy and gene editing

Dr Albert Seymour

14 June 2021

Interview

Viewpoint

The dose makes the poison: next generation AAV vectors can save the day

Julia Fakhiri,

Jihad El Andari

13 July 2021

Viewpoint

A bright future for lipid nanoparticles in gene therapy

Hongwei Zhang

9 July 2021

Viewpoint

Next-generation viral vector platforms for gene therapy, vaccine, and oncolytic virotherapy applications

Inanç Ortaç

21 June 2021

Viewpoint

FastFacts

Cell and gene manufacturing: a case study approach to overcoming challenges – expert perspectives and solutions

Steven Thompson

9 July 2021

FastFacts

Plasmid processing for mRNA, gene therapy and other vector applications

Henrik Ihre, PhD

1 July 2021

FastFacts

Vector characterization & analytics

Innovator Insight

Addressing the challenges of purification and quality control in gene therapy

Akash Bhattacharya,

Audrey Chang,

Leisha Kopp,

Klaus Richter,

Shawn Sternisha

24 August 2021

Innovator Insight

COVID-19 mRNA vaccine approvals: key lessons for cell & gene therapy and mRNA therapeutic development

Joseph Barberio,

Dr. Christoph Kröner ,

Venkata Indurthi, PhD,

Scott Zobbi

26 July 2021

Innovator Insight

Interview

The A to Z of QbD

Michael Lehmicke

15 June 2021

Interview

FastFacts

Development & validation of a robust commercial solution for measuring residual kanamycin-resistant plasmid DNA

Tania Chakrabarty

11 August 2021

FastFacts

Slope spectroscopy for gene therapy applications

Paul Mania

11 August 2021

FastFacts

Viewpoint

Recent evolution in Process Analytical Technology for viral vectors

Tony Bou Kheir

20 August 2021

Viewpoint

Regulatory Insights June 2021

Interview

Regulatory CMC in cell and gene therapy: navigating an evolving space

Lawrence C. Starke

26 May 2021

Interview

Innovator Insight

Lentiviral vectors: key challenges and new developments

Natalia Elizalde, PhD,

Juan Carlos Ramírez, PhD

23 June 2021

Innovator Insight

FastFacts

Mycoplasma detection in cell therapy products: GMP-compliant implementation & validation of a commercial real-time PCR assay for routine quality control & lot release

Valentina Becherucci

22 June 2021

FastFacts

Dedicated regulatory support packages for TheraPEAK® GMP Solutions

Hippolitus Odukwu

22 June 2021

FastFacts

Strategies to advance the donor selection process for cell therapies to improve outcomes

Martin Maiers, Vice President of Innovation, NMDP/Be The Match

Professor Effie Wang Petersdorf, Managing Director, Clinical Research Division, Fred Hutchinson Cancer Research Centre

Kim Wadsworth, Senior Immunogenetic Specialist, NMDP/Be The Match

Ray Sajulga, Jr, Bioinformatics Scientist, NMDP/Be The Match

17 June 2021

Webinar

Watch now

Addressing the challenges of purification & quality control in gene therapy

Dr. Akash Bhattacharya, Senior Application Engineer, Beckman Coulter

Leisha Kopp, Applications Scientist, Mirus Bio

Klaus Richter, PhD, Group Leader AUC, Coriolis Pharma

Dr. Audrey Chang, Vice President of Quality Control and Analytical Service, Vigene Biosciences

Shawn Sternisha, Senior Field Applications Scientist, Beckman Coulter Life Sciences

24 June 2021

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Jun 2021. Vol 7 Issue 6

FEATURING

Spotlight

Gene delivery platform evolution

Sponsor

Editorial

Expanding gene therapy and gene editing strategies to large and complex indications

Innovator Insight

Scalable upstream process development for the suspension-based production of lentiviral vectors for CAR T cell therapies with multiparallel & benchtop bioreactor systems & DoE methodology

Interview

Next steps in AAV preclinical and translational R&D

Coming of age: taking the next steps with non-viral gene delivery

Progressing genetic medicines at the interface of gene therapy and gene editing

Viewpoint

The dose makes the poison: next generation AAV vectors can save the day

A bright future for lipid nanoparticles in gene therapy

Next-generation viral vector platforms for gene therapy, vaccine, and oncolytic virotherapy applications

FastFacts

Cell and gene manufacturing: a case study approach to overcoming challenges – expert perspectives and solutions

Plasmid processing for mRNA, gene therapy and other vector applications

Vectors FOCUS

Vector characterization & analytics

Innovator Insight

Addressing the challenges of purification and quality control in gene therapy

COVID-19 mRNA vaccine approvals: key lessons for cell & gene therapy and mRNA therapeutic development

Interview

The A to Z of QbD

FastFacts

Development & validation of a robust commercial solution for measuring residual kanamycin-resistant plasmid DNA

Slope spectroscopy for gene therapy applications

Viewpoint

Recent evolution in Process Analytical Technology for viral vectors

Report

Regulatory Insights June 2021

Interview

Regulatory CMC in cell and gene therapy: navigating an evolving space

Other articles

Innovator Insight

Lentiviral vectors: key challenges and new developments

FastFacts

Mycoplasma detection in cell therapy products: GMP-compliant implementation & validation of a commercial real-time PCR assay for routine quality control & lot release

Dedicated regulatory support packages for TheraPEAK® GMP Solutions

Webinars

Strategies to advance the donor selection process for cell therapies to improve outcomes

Addressing the challenges of purification & quality control in gene therapy